This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Barr Raises Bid for Pliva

Barr Pharmaceuticals (BRL) appears ready to dig a little deeper in order to gain control of European generic-drug maker Pliva.

A day after Iceland's Actavis Group said it would offer $2.3 billion for the Croatian firm, Barr has matched the bid. Earlier this week, Barr proposed a plan to buy Pliva for $2.2 billion.

"As we stated when our initial offer was announced, we believe that Barr represents the best potential suitor for Pliva and provides significant value to Pliva's shareholders," said Bruce Downey, Barr's chairman and CEO, in a statement Friday.

Originally, Actavis had offered $1.6 billion, but Pliva's management said that was inadequate. The company raised its price after Barr made its intentions known.

Shares of New Jersey-based Barr were higher by 40 cents, or 0.8%, to $48.25 in light trading on the New York Stock Exchange.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AAPL $130.28 0.47%
FB $81.53 -1.07%
GOOG $565.06 3.30%
TSLA $218.42 -0.08%
YHOO $44.52 1.89%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs